JLE

European Journal of Dermatology

MENU

Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis Volume 28, numéro 3, May-June 2018

  • [1] Leiter U., Eigentler T., Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120-140.
  • [2] Rodriguez-Cuevas S., Barroso-Bravo S., Almanza-Estrada J., Cristobal-Martinez L., Gonzalez-Rodriguez E. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res. 2001;32:273-276.
  • [3] Hunger R.E., Angermeier S., Seyed Jafari S.M., Ochsenbein A., Shafighi M. A retrospective study of 1- versus 2-cm excision margins for cutaneous malignant melanomas thicker than 2 mm. J Am Acad Dermatol. 2015;72:1054-1059.
  • [4] Matthiessen L.W., Chalmers R.L., Sainsbury D.C. Management of cutaneous metastases using electrochemotherapy. Acta Oncol. 2011;50:621-629.
  • [5] Campana L.G., Valpione S., Mocellin S. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg. 2012;99:821-830.
  • [6] Okino M., Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res. 1987;78:1319-1321.
  • [7] Orlowski S., Belehradek J., Paoletti C., Mir L.M. Transient electropermeabilization of cells in culture: increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol. 1988;37:4727-4733.
  • [8] Mir L.M., Banoun H., Paoletti C. Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res. 1988;175:15-25.
  • [9] Seyed Jafari S.M., Shafighi M., Beltraminelli H., Geiser T., Hunger R.E., Gazdhar A. Improvement of flap necrosis in a rat random skin flap model by in vivo electroporation-mediated HGF gene transfer. Plast Reconstr Surg. 2017;139:1116e-1127e.
  • [10] Seyed Jafari S.M., Shafighi M., Beltraminelli H. Efficacy of in vivo electroporation-mediated IL-10 gene delivery on survival of skin flaps. J Membr Biol. 2018;251:211-219.
  • [11] Quaglino P., Mortera C., Osella-Abate S. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol. 2008;15:2215-2222.
  • [12] Gehl J., Geertsen P.F. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res. 2000;10:585-589.
  • [13] Rols M.P., Bachaud J.M., Giraud P., Chevreau C., Roche H., Teissie J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res. 2000;10:468-474.
  • [14] Gothelf A., Mir L.M., Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev. 2003;29:371-387.
  • [15] Marty M., Sersa G., Garbay J.R. Electrochemotherapy-An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl. 2006;4:3-13.
  • [16] Plaschke C.C., Gothelf A., Gehl J., Wessel I. Electrochemotherapy of mucosal head and neck tumors: a systematic review. Acta Oncol. 2016;55:1266-1272.
  • [17] Sersa G., Stabuc B., Cemazar M., Miklavcic D., Rudolf Z. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res. 2000;6:863-867.
  • [18] Mir L., Orlowski S., Belehradek J. Biomedical applications of electric pulses with special emphasis on antitumor electrochemotherapy. Bioelectrochem Bioenerg. 1995;38:203-207.
  • [19] Rols M.-P., Teissie J. Electropermeabilization of mammalian cells. Quantitative analysis of the phenomenon. Biophys J. 1990;58:1089.
  • [20] Sersa G., Stabuc B., Cemazar M., Miklavcic D., Rudolf Z. Electrochemotherapy with cisplatin: the systemic antitumor effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res. 2000;10:381-385.
  • [21] Mir L.M., Glass L.F., Sersa G. Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy. Br J Cancer. 1998;77:2336-2342.
  • [22] Heller R., Gilbert R., Jaroszeski M.J. Clinical applications of electrochemotherapy. Adv Drug Deliv Rev. 1999;35:119-129.
  • [23] Kaehler K.C., Egberts F., Hauschild A. Electrochemotherapy in symptomatic melanoma skin metastases: intraindividual comparison with conventional surgery. Dermatol Surg. 2010;36:1200-1202.
  • [24] Sersa G., Cemazar M., Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res. 1995;55:3450-3455.
  • [25] Heller R., Jaroszeski M., Perrott R., Messina J., Gilbert R. Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. Melanoma Res. 1997;7:10-18.
  • [26] Cemazar M., Milacic R., Miklavcic D., Dolzan V., Sersa G. Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness, sequence dependence and platinum content. Anticancer Drugs. 1998;9:525-530.
  • [27] Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
  • [28] DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
  • [29] Queirolo P., Marincola F., Spagnolo F. Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. Arch Dermatol Res. 2014;306:521-526.
  • [30] Rudolf Z., Stabuc B., Cemazar M., Miklavcic D., Vodovnik L., Sersa G. Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol. 1995;29:229-235.
  • [31] Tounekti O., Pron G., Belehradek J. Jr., Mir L.M. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res. 1993;53:5462-5469.
  • [32] Pron G., Belehradek J., Mir L. Identification of a plasma membrane protein that specifically binds bleomycin. Biochem Biophys Res Commun. 1993;194:333-337.
  • [33] Pron G., Belehradek J., Orlowski S., Mir L.M. Involvement of membrane bleomycin-binding sites in bleomycin cytotoxicity. Biochem Pharmacol. 1994;48:301-310.
  • [34] Poddevin B., Orlowski S., Belehradek J., Mir L. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol. 1991;42:S67-75.
  • [35] Belehradek J. Jr., Orlowski S., Ramirez L.H., Pron G., Poddevin B., Mir L.M. Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim Biophys Acta. 1994;1190:155-163.
  • [36] Gehl J., Geertsen P.F. Palliation of haemorrhaging and ulcerated cutaneous tumors using electrochemotherapy. EJC Suppl. 2006;4:35-37.
  • [37] Kis E., Olah J., Ocsai H. Electrochemotherapy of cutaneous metastases of melanoma--a case series study and systematic review of the evidence. Dermatol Surg. 2011;37:816-824.
  • [38] Glass L.F., Fenske N.A., Jaroszeski M. Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J Am Acad Dermatol. 1996;34:82-86.
  • [39] Heller R., Jaroszeski M.J., Glass L.F. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer. 1996;77:964-971.
  • [40] Ricotti F., Giuliodori K., Cataldi I. Electrochemotherapy: an effective local treatment of cutaneous and subcutaneous melanoma metastases. Dermatol Ther. 2014;27:148-152.
  • [41] Solari N., Spagnolo F., Ponte E. Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J Surg Oncol. 2014;109:270-274.
  • [42] Heller R., Jaroszeski M.J., Reintgen D.S. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer. 1998;83:148-157.
  • [43] Skarlatos I., Kyrgias G., Mosa E. Electrochemotherapy in cancer patients: first clinical trial in Greece. In Vivo. 2011;25:265-274.
  • [44] Bertino G., Sersa G., De Terlizzi F. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: results of the treatment of skin cancer. Eur J Cancer. 2016;63:41-52.
  • [45] Valpione S., Campana L.G., Pigozzo J., Chiarion-Sileni V. Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib. Radiol Oncol. 2015;49:71-74.
  • [46] Caraco C., Mozzillo N., Marone U. Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. BMC Cancer. 2013;13:564.
  • [47] Kreuter A., van Eijk T., Lehmann P. Electrochemotherapy in advanced skin tumors and cutaneous metastases - a retrospective multicenter analysis. J Dtsch Dermatol Ges. 2015;13:308-315.
  • [48] Hribernik A., Cemazar M., Sersa G., Bosnjak M., Snoj M. Effectiveness of electrochemotherapy after IFN-alpha adjuvant therapy of melanoma patients. Radiol Oncol. 2016;50:21-27.
  • [49] Campana L.G., Testori A., Curatolo P. Treatment efficacy with electrochemotherapy: a multi-institutional prospective observational study on 376 patients with superficial tumors. Eur J Surg Oncol. 2016;42:1914-1923.
  • [50] Fantini F., Gualdi G., Cimitan A., Giannetti A. Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy. Arch Dermatol. 2008;144:1186-1188.
  • [51] Salwa S.P., Bourke M.G., Forde P.F. Electrochemotherapy for the treatment of ocular basal cell carcinoma; a novel adjunct in the disease management. J Plast Reconstr Aesthet Surg. 2014;67:403-406.
  • [52] Kis E., Baltas E., Kinyo A. Successful treatment of multiple basaliomas with bleomycin-based electrochemotherapy: a case series of three patients with Gorlin-Goltz syndrome. Acta Derm Venereol. 2012;92:648-651.
  • [53] Macri G.F., Greco A., Gallo A., Fusconi M., Marinelli C., de Vincentiis M. Use of electrochemotherapy in a case of neck skin metastasis of oral squamous cell carcinoma: case report and considerations. Head Neck. 2014;36:E86-90.
  • [54] Gualdi G., Monari P., Fantini F., Cesinaro A.M., Cimitan A. Electrochemotherapy-induced virus disappearance in HHV-8-positive skin nodules of Kaposi sarcoma: first histological and immunohistochemical demonstration of efficacy. J Eur Acad Dermatol Venereol. 2010;24:239-241.
  • [55] Curatolo P., Quaglino P., Marenco F. Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol. 2012;19:192-198.
  • [56] Garbay J.-R., Billard V., Bernat C., Mir L.M., Morsli N., Robert C. Successful repetitive treatments by electrochemotherapy of multiple unresectable Kaposi sarcoma nodules. EJC Suppl. 2006;4:29-31.
  • [57] Curatolo P., Mancini M., Ruggiero A., Clerico R., Di Marco P., Calvieri S. Successful treatment of penile Kaposi's sarcoma with electrochemotherapy. Dermatol Surg. 2008;34:839-842. discussion: 42-3
  • [58] Di Monta G., Caraco C., Benedetto L. Electrochemotherapy as “new standard of care” treatment for cutaneous Kaposi's sarcoma. Eur J Surg Oncol. 2014;40:61-66.
  • [59] Latini A., Bonadies A., Trento E. Effective treatment of Kaposi's sarcoma by electrochemotherapy and intravenous bleomycin administration. Dermatol Ther. 2012;25:214-218.
  • [60] Curatolo P., Mancini M., Clerico R. Remission of extensive Merkel cell carcinoma after electrochemotherapy. Arch Dermatol. 2009;145:494-495.
  • [61] Scelsi D., Mevio N., Bertino G. Electrochemotherapy as a new therapeutic strategy in advanced Merkel cell carcinoma of head and neck region. Radiol Oncol. 2013;47:366-369.
  • [62] Larkin J.O., Collins C.G., Aarons S. Electrochemotherapy: aspects of preclinical development and early clinical experience. Ann Surg. 2007;245:469-479.
  • [63] Bourke M.G., Salwa S.P., Sadadcharam M. Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: ten-year audit of single centre experience. Breast Cancer Res Treat. 2017;161:289-297.
  • [64] Whelan M.C., Larkin J.O., Collins C.G. Effective treatment of an extensive recurrent breast cancer which was refractory to multimodal therapy by multiple applications of electrochemotherapy. EJC Suppl. 2006;4:32-34.
  • [65] Campana L.G., Valpione S., Falci C. The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study. Breast Cancer Res Treat. 2012;134:1169-1178.
  • [66] Matthiessen L.W., Johannesen H.H., Hendel H.W., Moss T., Kamby C., Gehl J. Electrochemotherapy for large cutaneous recurrence of breast cancer: a phase II clinical trial. Acta Oncol. 2012;51:713-721.
  • [67] Benevento R., Santoriello A., Perna G., Canonico S. Electrochemotherapy of cutaneous metastastes from breast cancer in elderly patients: a preliminary report. BMC Surg. 2012;12:S6.
  • [68] Cabula C., Campana L.G., Grilz G. Electrochemotherapy in the treatment of cutaneous metastases from breast cancer: a multicenter cohort analysis. Ann Surg Oncol. 2015;22:S442-S450.
  • [69] Campana L.G., Bianchi G., Mocellin S. Electrochemotherapy treatment of locally advanced and metastatic soft tissue sarcomas: results of a non-comparative phase II study. World J Surg. 2014;38:813-822.
  • [70] Gatti A., Stinco G., Trevisini S. Electrochemotherapy as a novel treatment for primary cutaneous marginal zone B-cell lymphomas. Dermatol Ther. 2014;27:244-247.
  • [71] Guida M., Campana L.G., Curatolo P. Local treatment with electrochemotherapy of superficial angiosarcomas: efficacy and safety results from a multi-institutional retrospective study. J Surg Oncol. 2016;114:246-253.
  • [72] Kubota Y., Mir L.M., Nakada T., Sasagawa I., Suzuki H., Aoyama N. Successful treatment of metastatic skin lesions with electrochemotherapy. J Urol. 1998;160:1426.
  • [73] Snoj M., Cemazar M., Srnovrsnik T., Kosir S.P., Sersa G. Limb sparing treatment of bleeding melanoma recurrence by electrochemotherapy. Tumori. 2009;95:398-402.
  • [74] Kubota Y., Tomita Y., Tsukigi M., Kurachi H., Motoyama T., Mir L.M. A case of perineal malignant melanoma successfully treated with electrochemotherapy. Melanoma Res. 2005;15:133-134.
  • [75] Lido P., Paolino G., Feliziani A. Cutaneous metastasis of unknown primary presenting as massive and invasive abdominal lesion: an elective approach with electrochemotherapy. An Bras Dermatol. 2015;90:879-882.
  • [76] Escoffre J.M., Rols M.P. Electrochemotherapy: progress and prospects. Curr Pharm Des. 2012;18:3406-3415.
  • [77] Cemazar M., Miklavcic D., Vodovnik L. Improved therapeutic effect of electrochemotherapy with cisplatin by intratumoral drug administration and changing of electrode orientation for electropermeabilization on EAT tumor model in mice. Radiol Oncol. 1995;29:121-127.
  • [78] Sersa G., Stabuc B., Cemazar M., Jancar B., Miklavcic D., Rudolf Z. Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients. Eur J Cancer. 1998;34:1213-1218.
  • [79] Snoj M., Rudolf Z., Cemazar M., Jancar B., Sersa G. Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anticancer Drugs. 2005;16:345-348.
  • [80] Rebersek M., Cufer T., Cemazar M., Kranjc S., Sersa G. Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer Drugs. 2004;15:593-597.
  • [81] Mir L.M., Gehl J., Sersa G. Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator TM by means of invasive or non-invasive electrodes. EJC Suppl. 2006;4:14-25.
  • [82] Testori A., Tosti G., Martinoli C. Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther. 2010;23:651-661.
  • [83] Mir L.M. Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry. 2001;53:1-10.
  • [84] Miklavčič D., Serša G., Brecelj E. Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Med Biol Eng Comput. 2012;50:1213-1225.
  • [85] Domenge C., Orlowski S., Luboinski B. Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer. 1996;77:956-963.
  • [86] Miklavcic D., Corovic S., Pucihar G., Pavselj N. Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy. EJC Suppl. 2006;4:45-51.
  • [87] Gehl J., Sorensen T.H., Nielsen K. In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta. 1999;1428:233-240.
  • [88] Ramirez L.H., Orlowski S., An D. Electrochemotherapy on liver tumours in rabbits. Br J Cancer. 1998;77:2104-2111.
  • [89] Snoj M., Cemazar M., Kolar B.S., Sersa G. Effective treatment of multiple unresectable skin melanoma metastases by electrochemotherapy. Croat Med. 2007;48:391.
  • [90] Campana L.G., Testori A., Mozzillo N., Rossi C.R. Treatment of metastatic melanoma with electrochemotherapy. J Surg Oncol. 2014;109:301-307.
  • [91] Miklavcic D., Pucihar G., Pavlovec M. The effect of high frequency electric pulses on muscle contractions and antitumor efficiency in vivo for a potential use in clinical electrochemotherapy. Bioelectrochemistry. 2005;65:121-128.
  • [92] Sersa G., Cemazar M., Rudolf Z. Electrochemotherapy: advantages and drawbacks in treatment of cancer patients. Cancer Ther. 2003;1:133-142.
  • [93] Glass L.F., Jaroszeski M., Gilbert R., Reintgen D.S., Heller R. Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol. 1997;37:596-599.
  • [94] Byrne C.M., Thompson J.F., Johnston H. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanom Res. 2005;15:45-51.
  • [95] Gaudy C., Richard M.A., Folchetti G., Bonerandi J.J., Grob J.J. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg. 2006;10:115-121.
  • [96] Tijink B.M., De Bree R., Van Dongen G.A., Leemans C.R. How we do it: chemo-electroporation in the head and neck for otherwise untreatable patients. Clin Otolaryngol. 2006;31:447-451.
  • [97] Glass L.F., Pepine M.L., Fenske N.A., Jaroszeski M., Reintgen D.S., Heller R. Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol. 1996;132:1353-1357.
  • [98] Belehradek M., Domenge C., Luboinski B., Orlowski S., Belehradek J. Jr., Mir L.M. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer. 1993;72:3694-3700.
  • [99] Landstrom F.J., Nilsson C.O., Crafoord S., Reizenstein J.A., Adamsson G.B., Lofgren L.A. Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg. 2010;36:1245-1250.
  • [100] Marenco F., Nardo T., Savoia P., Bernengo M.G. Effectiveness of electrochemotherapy in treatment of a recurrent squamous cell carcinoma of the scalp. Eur J Dermatol. 2011;21:618-619.
  • [101] Quaglino P., Matthiessen L.W., Curatolo P. Predicting patients at risk for pain associated with electrochemotherapy. Acta Oncol. 2015;54:298-306.
  • [102] Campana L.G., Mocellin S., Basso M. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surgical Oncol. 2009;16:191-199.
  • [103] Garbe C., Eigentler T.K. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17:117-127.
  • [104] Jarm T., Cemazar M., Miklavcic D., Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther. 2010;10:729-746.
  • [105] Sersa G., Cemazar M., Snoj M. Electrochemotherapy of tumours. Curr Oncol. 2009;16:34-35.
  • [106] Sersa G., Cemazar M., Parkins C.S., Chaplin D.J. Tumor blood flow changes induced by application of electric pulses. Eur J Cancer. 1999;35:672-677.
  • [107] Mali B., Jarm T., Snoj M., Sersa G., Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol. 2013;39:4-16.
  • [108] Mir-Bonafe J.M., Vilalta A., Alarcon I. Electrochemotherapy in the treatment of melanoma skin metastases: a report on 31 cases. Actas Dermosifiliogr. 2015;106:285-291.
  • [109] Allegretti J.P., Panje W.R. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope. 2001;111:52-56.
  • [110] Sersa G. The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses. EJC Suppl. 2006;4:52-59.
  • [111] Gilbert R.A., Jaroszeski M.J., Heller R. Novel electrode designs for electrochemotherapy. Biochim Biophys Acta. 1997;1334:9-14.
  • [112] Testori A., Faries M.B., Thompson J.F. Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol. 2011;104:391-396.
  • [113] Byrne C.M., Thompson J.F. Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Rev Anticancer Ther. 2006;6:671-678.
  • [114] Kunte C., Letule V., Gehl J. Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT. Br J Dermatol. 2017;176:1475-1485.
  • [115] Mir L.M., Orlowski S., Poddevin B., Belehradek J. Jr. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses. Eur Cytokine Netw. 1992;3:331-334.
  • [116] Mir L.M., Roth C., Orlowski S. Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2. C R Acad Sci III. 1992;314:539-544.
  • [117] Mir L.M., Roth C., Orlowski S. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J Immunother Emphasis Tumor Immunol. 1995;17:30-38.
  • [118] Spanggaard I., Gehl J. Antiangiogenic metargidin peptide (AMEP) gene therapy in disseminated melanoma. Methods Mol Biol. 2015;1317:359-364.
  • [119] Daud A.I., DeConti R.C., Andrews S. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008;26:5896-5903.
  • [120] Mir L.M. Electroporation-based gene therapy: recent evolution in the mechanism description and technology developments. Methods Mol Biol. 2014;1121:3-23.
  • [121] Gehl J. Gene electrotransfer in clinical trials. Methods Mol Biol. 2014;1121:241-246.
  • [122] Testori A., Rossi C.R., Tosti G. Utility of electrochemotherapy in melanoma treatment. Curr Opin Oncol. 2012;24:155-161.
  • [123] Mozzillo N., Simeone E., Benedetto L. Assessing a novel immuno-oncology-based combination therapy: ipilimumab plus electrochemotherapy. Oncoimmunology. 2015;4:e1008842.